SynthesisMedicine2019
Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Exploring the therapeutic potential of "Xiaochaihu Decoction": a systematic review and meta-analysis on the clinical effectiveness and safety in managing cancer-related fever.Frontiers in pharmacology · 2024Pooled it
- Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study.The oncologist · 2026Article
- Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.Cancer management and research · 2026Review
- Case Report: Triple-negative metaplastic breast carcinoma with primary resistance to neoadjuvant chemoimmunotherapy, refractory tumor necrosis-related fever, and rapid postoperative disease progression.Frontiers in oncology · 2026Article
- Thyroid angiosarcoma: a rare malignancy - case report and systematic review of the literature.Thyroid research · 2025Review
- Clinical features, procalcitonin concentration, and bacterial infection in febrile hospitalized cancer patients: a descriptive study and association analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Distribution of the causes of fever of unknown origin in China, 2013-2022.Journal of translational internal medicine · 2024Article
- ThermoPCD: a database of molecular dynamics trajectories of antibody-antigen complexes at physiologic and fever-range temperatures.Database : the journal of biological databases and curation · 2024Article
- Cucurbituril-assisted sensitive fluorescence detection and quantitation of naproxen drug in wastewater samples: Guest-host characterization and HPLC investigation.Frontiers in chemistry · 2022Article
- [The Effects and Management of Viral Pneumonia on Lung Cancer Patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Successful Treatment of Neoplastic Fever with Oxybutynin.Journal of palliative medicine · 2019Article
- Naproxen in High-Temperature Neoplastic Fever: A Case Report Highlighting Its Distinctive Profile among Nonsteroidal Anti-Inflammatory Drugs.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of naproxen on the treatment of neoplastic fever is still unclear. A systematic review and meta-analysis were performed to investigate the effect of naproxen in the treatment of cancer fever or suspicion. Besides, the latest and most convincing evidence was provided for the earlier use of naproxen in treating cancer patients with fever of unknown origin.
methodsA literature review was conducted to identify all published studies on the naproxen for the treatment of neoplastic fever. Electronic databases (eg, PUBMED, EMBASE and the Cochrane Library) were searched until October 2018. Data were extracted, and the risk of bias was assessed by 2 authors independently. Standard meta-analyses on the rate of successful treatment were conducted using a random-effects model, and relative risks were calculated with 95% confidence intervals (CIs).
resultsA total of 15 studies, recruiting 582 participants, were included, which were 1 randomized controlled trial (RCT), 1 non-RCT, 3 cross-sectional studies, and 10 case-series studies. The result of our meta-analysis revealed that the success rate on the treatment of neoplastic fever using naproxen was 94.1% (95% CI: 87.6%-97.3%). The success rate of the suspected neoplastic fever was 79.8%; for fever of unknown origin, it also reached 67.7%. In this meta-analysis, the success rate was 98.1% (95% CI: 95.0%-99.3%) in the dosage of 250 mg twice a day. Besides, a small dose of 125 mg naproxen, 375 mg twice a day and 250 mg 3 times a day were also useful. The result of the subgroup analysis revealed that the difference was not statistically significant in the treatment success rate for solid tumors and hematologic malignant.
conclusionsThe result of our meta-analysis suggested that naproxen exhibited a highly successful rate for the treatment of neoplastic fever. Besides, naproxen was also satisfactory in improving symptoms of suspected neoplastic fever and fever of unknown origin. The earlier use of naproxen might be able to mitigate cancer patient's suffering and enhanced their quality of life. These findings, however, rely primarily on observational data and should be interpreted rigorously. Further well-conducted trials are required to assess naproxen for the treatment of neoplastic fever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.